Avapritinib is a highly selective, potent inhibitor of the D816V mutated KIT oncogene able to reduce serum tryptase and bone marrow mast cell counts by at least 50% in SM according to randomized placebo-controlled studies [5–7]. The gene discussed is KIT; the disease is systemic mastocytosis.